Histone deacetylase 6 (HDAC6) is a unique enzyme with specific structural and functional features. It is actively or stably maintained in the cytoplasm and is the only member, within the histone deacetylase family, that harbors a full duplication of its deacetylase homology region followed by a specific ubiquitin-binding domain at the C-terminus end. Accordingly, this deacetylase functions at the heart of a cellular regulatory mechanism capable of coordinating various cellular functions largely relying on the microtubule network. Moreover, HDAC6 action as a regulator of the HSP90 chaperone activity adds to the multifunctionality of the protein, and allows us to propose a critical role for HDAC6 in mediating and coordinating various cellular events in response to different stressful stimuli.
Introduction
Protein lysine acetylation is now emerging as a widely occurring post-translational modification and constitutes a genuine cellular signaling system involved in the control of various functions in different cellular compartments (reviewed in Kouzarides, 2000; Sterner and Berger, 2000; Caron et al., 2003; Yang, 2004; Glozak et al., 2005) . Originally, lysine acetylation, mainly that of histones and transcription factors, was regarded as a powerful mean of gene expression regulation. Rapid progress in the discovery and functional analysis of an increasing number of nuclear enzymes involved in protein lysine acetylation and deacetylation, histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively, have demonstrated that these enzymes, independently of transcription, can control some of the basic cellular processes such as protein stability (reviewed in Caron et al., 2005) . Moreover, it is now clear that acetylation is not an exclusive modification of nuclear proteins, since many cytoplasmic proteins, including a significant subset of mitochondrial proteins, have recently been shown to bear lysine acetylation (Cohen et al., 2004; Dihazi et al., 2005; Iwabata et al., 2005; Kovacs et al., 2005; Hallows et al., 2006; Kim et al., 2006; Schwer et al., 2006) . The regulation of these acetylations and the determination of their functional significance now constitute a real challenge for biologists. In fact, while the list of cytoplasmic acetylated proteins is rapidly growing, basic information on the involved enzymatic machinery, HATs and HDACs, as well as on their functions, is still missing.
The identification of HDAC6 as the first HDAC actively maintained in the cytoplasm (Verdel et al., 2000) opened the way for the identification of its substrates and cellular functions controlled by its catalytic activity in this compartment. Further analyses of HDAC6 functions revealed the involvement of the protein in cellular processes dependent and independent of its catalytic activity. Indeed, the discovery of an ubiquitin-binding domain in HDAC6 (Seigneurin-Berny et al., 2001) led to the unraveling of its participation in cellular functions depending on cell signaling through protein ubiquitination (Kawaguchi et al., 2003; Boyault et al., 2006) . HDAC6 therefore appears as a protein functioning at the crossroads between at least two cellular signaling systems, respectively, involving protein lysine acetylation and ubiquitination.
HDAC6 is not the only cytoplasmic deacetylase. In fact, early investigations showed that under specific circumstances, other HDACs of different classes could also be found in the cytoplasm. However, their cytoplasmic functions remain elusive and except for SIRT2, a class III HDAC member (North et al., 2003) , none of the HDAC6 activities seems to be shared by these enzymes (Hubbert et al., 2002; Matsuyama et al., 2002) . Among them, HDAC10 deserves a special attention since it is the closest relative of HDAC6. Indeed, the HDAC10 catalytic domain shows the highest homology to those of HDAC6 and, moreover, its pseudo-duplication is reminiscent of HDAC6 catalytic domain duplication. This characteristic of HDAC10 justifies a close examination of the known HDAC10 activities in the light of data available on HDAC6 functions. This review will therefore essentially consider the important body of data now available on HDAC6 since its discovery in 1999 (Grozinger et al., 1999; Verdel and Khochbin, 1999) , aiming to draw a synthetic scheme of its cellular functions and highlight its possible involvement in human pathologies.
Domain organization and structural features of HDAC6
HDAC6 is the only member of the cellular deacetylase family containing a full duplication of the large class I/II HDAC-homology domain (Figure 1 ), first revealed in the mouse HDAC6 (Verdel and Khochbin, 1999) and then in its human ortholog (Grozinger et al., 1999) . This feature could be considered as a unique signature allowing the identification of HDAC6 orthologs in other species including invertebrates, Drosophila melanogaster and Caenorhabditis elegans as well as in plants such as Arabidopsis thaliana (Barlow et al., 2001; reviewed in Yang and Gregoire, 2005) .
The conservation of the double catalytic domain organization during evolution strongly argues in favor of a critical role for this domain duplication in HDAC6 functions and prompted the investigators to uncover its role in the whole deacetylase activity of the enzyme. One obvious way to tackle this issue consisted in the measurement of the deacetylase activity of HDAC6 mutants containing inactivating mutations in each domain individually. Unexpectedly, these experiments generated conflicting results. The first attempt showed that each domain possessed an independent catalytic activity (Grozinger et al., 1999) . This result was, however, challenged by other groups showing that the HDAC activity of HDAC6 relies either on the integrity of both HDAC domains (Zhang et al., 2003 or is mediated by its second catalytic domain (Zou et al., 2006) . The discovery of a-tubulin as an HDAC6 substrate (Hubbert et al., 2002; Matsuyama et al., 2002; Zhang et al., 2003) allowed researchers to also include acetylated tubulin in these assays (Haggarty et al., 2003; Zhang et al., 2003 Zhang et al., , 2006 Zou et al., 2006) . Here again, some of the investigators found that the integrity of both HDAC6 catalytic domains was indispensable for the whole tubulin deacetylase (TDAC) activity of the enzyme (Zhang et al., 2003 , whereas others showed that the whole TDAC activity could be attributed to the second domain (Haggarty et al., 2003; Zou et al., 2006) .
Additional investigations revealed the existence of other structural requirements for an efficient HDAC and TDAC activity of HDAC6. Indeed, the spacer region between the two catalytic domains of the protein was found to play a crucial role in the total activity of HDAC6, and amino acid addition or deletion in this region dramatically affected the TDAC activity of HDAC6. The HDAC activity of HDAC6 seemed, however, to be less dependent on the length of this linker region than its TDAC activity . These studies also evidenced an important role for a conserved region present in HDACs and some HATs, known as substrate recognition site or Esa1-Rpd3 (ER) motif (Adachi et al., 2002) . Both HDAC and TDAC activities of HDAC6 rely on this motif present in each domain, but the ER in the second HDAC domain has a particularly critical role in TDAC activity of the enzyme .
Overall, despite these contradictory data, the second domain of HDAC6 seems to have a determinant role in at least the total TDAC activity of the enzyme (Haggarty et al., 2003; Zhang et al., 2006; Zou et al., 2006) .
In addition to HDAC6 catalytic activities, the control of its intra-cellular localization was also found to be an important issue in the understanding of its functions. Early investigations considering mouse HDAC6 showed that the protein is actively retained in the cytoplasm and could, only under specific circumstances, be partially found in the nucleus (Verdel et al., 2000) . Indeed, a strong nuclear export signal (NES) located N terminus to the first catalytic domain prevents the accumulation of the protein in the nucleus (Figure 1 ). Interestingly, although this N-terminus NES is conserved in human HDAC6 (hHDAC6), another region of the protein was found to ensure a stable anchorage of the protein in the cytoplasm (Figure 1 ). This domain, which has not so far been found in other HDAC6 orthologs, is characterized by eight consecutive tetradecapeptide repeat motifs, named SE14 (Bertos et al., 2004) .
The multiplication of domains and motifs, such as NES and the SE14, involved in the active and stable maintenance of hHDAC6 in the cytoplasm, suggest that during evolution a pressure appeared on HDAC6 to exclude the protein from the nucleus and to reinforce its cytoplasmic localization. HDAC6 is the only member of the histone deacetylase family containing tandem catalytic domains. So far two in vivo substrates, a-tubulin and HSP90, have been identified. In human HDAC6, two different domains ensure a stable maintenance of the protein in the cytoplasm. A conserved nuclear export signal (NES), functional in mouse and human HDAC6, mediates an active export of the protein from the nucleus. Only in human HDAC6, an additional domain, named SE14, has been found to stably anchor the protein in the cytoplasm. In the C-terminus part of the protein a domain, conserved in HDAC6 orthologs in many species, ZnF-UBP, constitutes a high affinity ubiquitin-binding motif. DD1 and DD2 stand for deacetylase domains 1 and 2, respectively, SE14 for Ser-Glu-containing tetradecapeptide and ZnF-UBP for ubiquitin C-terminus hydrolase-like zinc finger.
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Another remarkable aspect of HDAC6 is the presence of a conserved cysteine-and histidine-rich domain in its C-terminus part (Figure 1 ), which is also present in a group of ubiquitin-specific proteases (USP), named ZnF-UBP (Amerik et al., 2000; Seigneurin-Berny et al., 2001) . This domain has the particularity to specifically bind mono- (Seigneurin-Berny et al., 2001; Boyault et al., 2006) and poly-ubiquitin chains (Hook et al., 2002; Boyault et al., 2006) . More detailed studies allowed for the modeling of the structure of this domain in HDAC6 and to predict its organization in three zinc fingers. This particular organization of HDAC6 ZnF-UBP domain allows its binding to monomeric ubiquitin with a measured K d of 60 nM, which is the highest known affinity for ubiquitin binding among all known ubiquitin-interacting proteins (Boyault et al., 2006) .
Ubiquitin-dependent functions of HDAC6
HDAC6 not only binds mono-and poly-ubiquitin chains, but it also forms a complex, at least in the cytosol of cells from mouse testis, with two proteins that have obvious links to cellular ubiquitin-dependent functions. Purification of an endogenous HDAC6 complex from mouse testis cytosolic extracts revealed the presence of two components identified as p97/VCP, the mouse ortholog of yeast Cdc48, and phopholipase A2 activating protein (PLAP), the ortholog of yeast Ufd3 (Seigneurin-Berny et al., 2001) .
A recent work in yeast showed that both Cdc48 and Ufd3 are at the heart of an important decision center, which may determine whether a multi-ubiquitinated protein would be targeted for degradation to the proteasome or be deubiquitinated and eventually functionally recycled (Rumpf and Jentsch, 2006) . Although this mechanism has not yet been evidenced in higher eukaryotes, the investigation of the ubiquitindependent functions of HDAC6 has also recently revealed its involvement in the determination of the fate of ubiquitinated proteins. High-affinity binding of HDAC6 to ubiquitin was shown to hinder the recognition of cellular ubiquitinated proteins by other ubiquitin-binding factors and to subsequently delay their processing by the proteasome or USPs (Boyault et al., 2006) . The HDAC6 partner p97/VCP is a chaperone involved in the control of a variety of cellular functions, many of them relying on its 'segregase' activity disassembling various complexes, including those containing ubiquitinated proteins (Wang et al., 2003; Romisch, 2005) . p97/VCP, upon its binding to HDAC6, is able to extract HDAC6 bound to ubiquitinated proteins and therefore allows their further processing. A finely tuned equilibrium of cellular concentrations of HDAC6 and p97/VCP could therefore be critical in the determination of the fate of ubiquitinated cellular proteins, mostly consisting of misfolded proteins (Goldberg et al., 2002 ). An excess of HDAC6 would favor their accumulation in cells, while an increase of the p97/VCP concentration would accelerate the processing of these proteins (Boyault et al., 2006 ; Figure 2 ).
The ubiquitin-binding activity of HDAC6 has also been shown to be critical for its recently discovered function as an adapter, mediating the transport of ubiquitinated proteins along microtubule tracks to pericentriolar structures called aggresomes (Kawaguchi et al., 2003) . Through its simultaneous interaction with ubiquitin and dynein motors, HDAC6 is thought to help in building up a cellular protective response to the accumulation of cytotoxic protein aggregates scattered in the cytoplasm by mediating their transport to aggresomes (Kawaguchi et al., 2003) . Importantly, this ubiquitin-dependent function of HDAC6 is also linked to its catalytic activity, which is discussed in more detail below.
Deacetylase-dependent functions of HDAC6
Despite a strong in vitro histone-deacetylase activity of HDAC6, there has been no evidence for its activity in vivo (Haggarty et al., 2003; Zhang et al., 2003) . In the cells, HDAC6, therefore, appears to catalyse the removal of acetyl groups from substrates other than histones. The identification of two physiological substrates of HDAC6, a-tubulin and HSP90, has opened the way for the identification of a whole set of new cellular functions associated with HDAC6 catalytic activity. HDAC6, a coordinator of cell responses to stressful stimuli C Boyault et al
The first identified physiological substrate of HDAC6 was a-tubulin (Hubbert et al., 2002; Matsuyama et al., 2002; Zhang et al., 2003) . Although this finding was an important step forward to understand the mechanisms controlling tubulin acetylation, its functional implications remained obscure. The major reason was that, up to very recently, no function for tubulin acetylation could be evidenced. Interestingly, a recent work has reported that the tubulin binding and motility of kinesin-1 is controlled by a-tubulin acetylation (Reed et al., 2006) . Kinesins, like dynein, are involved in the transport of cargos along microtubule tracks. This study showed that inhibition of HDAC6 by specific inhibitors induces the transport of a kinesin-1 cargo protein, JIP1 (JNK-interacting protein 1), to neurites and its accumulation in neurite-tips (Reed et al., 2006) . This is the first evidence for a functional consequence of the TDAC activity of HDAC6. Indeed, the preferential binding of kinesin-1 to acetylated a-tubulin is proposed to mediate the effect of HDAC6 inhibition on JIP1 transport. Likewise, the acetylation-dependent binding of kinesins or other molecular motors and microtubule-associated proteins to tubulin may provide an explanation for the reported effects of HDAC6 catalytic activity on the transport of protein aggregates to aggresomes (Kawaguchi et al., 2003) , on the recruitment of the autophagic machinery to aggresomes (Iwata et al., 2005) , on cell motility (Hubbert et al., 2002; Haggarty et al., 2003) , on the organization of the immune synapse in T cells (Serrador et al., 2004) and on the polarized release of cytokine-containing secretory lysosomes (Carta et al., 2006) .
It is important, however, to note that not all the cytoskeleton-dependent functions of HDAC6 could be attributed to its TDAC activity. Indeed, Cabrero et al. (2006) have recently found that the cellular levels of HDAC6 and not its catalytic activity are critical for lymphocyte chemotaxis.
It is also noteworthy that the involvement of the actin cytoskeleton in cell migration is well established (Pantaloni et al., 2001; Pollard and Borisy, 2003) and that HDAC6 has also the potential to link actin filaments and microtubule dynamics through its interaction with formin homology proteins, mDia1 and mDia2, controlling actin polymerization (Destaing et al., 2005; Bershadsky et al., 2006) . Therefore, in addition to microtubules, HDAC6-dependent control of cell migration could involve the actin cytoskeleton and their functional interconnections.
Overall, these data point to HDAC6, and more specifically to its TDAC activity, as an important determinant of microtubule-dependent intracellular trafficking and consequently of various cellular functions depending on this process.
The second HDAC6 substrate is the well-characterized chaperone HSP90 (Bali et al., 2005; Kovacs et al., 2005; Murphy et al., 2005) . A recent thorough study showed that in yeast, HSP90 physically or genetically interacts with at least 10% of the yeast proteome . It therefore appears obvious that HSP90 should be considered as a master regulator of many essential regulatory processes. Among other functions, HSP90 seems to be specialized in stabilizing metastable regions of specific factors by keeping them in a 'holding' position. This is the case of glucocorticoid receptor (GR) whose hormone-binding activity depends on its association with HSP90, which keeps the protein in an inactive form in the cytoplasm (Pratt and Toft, 2003) . The HDAC6-regulated acetylation of HSP90 was shown to induce the dissociation of its cochaperone p23 and the accumulation of GRs defective in hormone binding Murphy et al., 2005) . Interestingly, the acetylation of HSP90 was also a major cause of instability of some of its client proteins with critical roles in cell growth and survival (reviewed in Caron et al., 2005) . However, importantly, HSP90 probably contains multiple acetylation sites (Scroggins et al., 2007) and not all are deacetylated by HDAC6. Indeed, although the HDAC inhibitor FK228 is not able to inhibit HDAC6 activity (Furumai et al., 2002) , it induces an increase in HSP90 acetylation (Blagosklonny, 2002) . Furthermore, an HDAC6-dependent acetylation of HSP90 may also act only on a subset of the HSP90 client proteins, since no correlation was observed between HSP90 acetylation in HDAC6 KO cells and the activity of one of its client proteins, the heat shock factor protein 1 (C Boyault and S Khochbin, unpublished data).
Nuclear targets of HDAC6
Despite the active and stable maintenance of mouse, human (Verdel et al., 2000; Bertos et al., 2004) and probably Drosophila (Barlow et al., 2001 ) HDAC6 in the cytoplasm, several reports have evidenced its impact on the transcriptional activities of various factors. Some of these effects may be indirect and attributed to the activity of HDAC6 as a regulator of HSP90 chaperone functions Murphy et al., 2005; Hurst et al., 2006; Kong et al., 2006) .
Beside these indirect effects, HDAC6 also seems to directly control the transcriptional repressor activities of several transcriptional regulators. Indeed, HATs p300 and CBP, in addition to their well-known transcriptional activator functions, show the ability to repress transcription. Sumoylation of the CRD1 domain of p300 was shown to mediate this repressor activity. In vitro and in vivo studies suggested that a direct binding of HDAC6 to SUMO-CRD1 could be responsible for the observed transcription repression by the CRD1 domain of p300 (Girdwood et al., 2003) , and further investigations suggested that this mechanism could be involved in the repression of at least two cellular genes (Ling and Lobie, 2004; Ma et al., 2005) .
HDAC6 was also found to be associated with transcriptional corepressors such as LCoR, which is involved in a ligand-dependent repressor activity of nuclear receptors (Fernandes et al., 2003) as well as in that of ETO-2, a component of N-CoR, SMRT and mSin3A complexes (Amann et al., 2001) . The repressor activity of individual transcription factors has also been attributed to their association with HDAC6. This is the case of Runx2, capable of both transcriptional activation and repression. A direct Runx2-dependent recruitment of HDAC6 from cytoplasm to chromatin could mediate the specific repression of p21 CIP/WAF (Westendorf et al., 2002) . Nuclear factor-kB (NF-kB) p50 and p65 also seem to recruit HDAC6 to repress the expression of a gene encoding a subunit of an H þ -K þ -ATPase (Zhang and Kone, 2002) . In contrast, the knockdown of HDAC6 had little effect on the double-stranded RNA (dsRNA)-induced activation of NF-kB, but severely interfered with the activity of IRF3, suggesting a positive role for HDAC6 in dsRNA/virus-dependent activation of IRF3 and the b-interferon gene response (Nusinzon and Horvath, 2006) . Here, however, it is not clear whether the action of HDAC6 is direct or mediated indirectly by its cytoplasmic activities.
It would be interesting to know, despite its active or stable maintenance in the cytoplasm, how various transcriptional regulatory factors described above could recruit HDAC6 to chromatin. The cytoplasmic localization of HDAC6 is, however, not exclusive. Indeed, in the mouse a fraction of HDAC6 has been reported to enter the nucleus under specific circumstances, for instance after butyrate-induced B16 cell differentiation (Verdel et al., 2000) . Additionally, although the SE14 domain of human HDAC6 is responsible for a stable cytoplasmic anchoring of the protein (Bertos et al., 2004) , an unknown cellular mechanism might modulate the activity of this domain and allow the nuclear localization of a fraction of HDAC6. Accordingly, an in situ analysis of hHDAC6 intracellular localization showed the dependence of this localization on the state of cell malignancy in mammary epithelial cells: the occurrence of a strong cytoplasmic staining in cancer and a preferential nuclear staining in normal cells was observed (Yoshida et al., 2004) .
It is also noteworthy that HDAC6 has been found to interact with two other HDACs. One of them is SIRT2. Like HDAC6, SIRT2 is a TDAC (North et al., 2003) . The other HDAC6-interacting HDAC, HDAC11, is of unknown function but may act as transcription repressor (Gao et al., 2002) . All together, these data may suggest a concerted action of HDAC6 and its interacting HDACs.
HDAC6: a therapeutic target?
Several investigations designed HDAC6 as a cellular factor with potential anti-viral activities. This could depend on its function as a regulator of the cytoskeleton, or on its direct or indirect involvement in transcriptional regulation. Indeed, cytoskeleton-dependent functions of HDAC6 have been shown to be crucial in HIV-1 infection of CD4 þ cells. An HDAC6-dependent increase in tubulin acetylation occurs following HIV-1 Env-CD4 receptor interaction in the CD4 þ cells, which could be an important event in HIV-1 cell fusion and infection (Valenzuela-Fernandez et al., 2005) . Accordingly, HDAC6 downregulation or the inhibition of its catalytic activity by a specific drug significantly stimulates HIV-1 infection (Valenzuela-Fernandez et al., 2005) .
HDAC6 activity not only counteracts viral infection but its functions also appear crucial for the activity of virus-specific cytotoxic T lymphocytes (CTL) to clear the infected cells. For instance, the specific inhibition of HDAC6 has been shown to greatly reduce the efficiency of CD8
þ CTLs in clearing human T-lymphotropic virus type-1 (HTLV-1)-infected cells (Mosley et al., 2006) .
Finally, the positive role of HDAC6 in the activation of the IRF3 transcription factor and the induction of b-interferon gene expression in response to viral infection (Nusinzon and Horvath, 2006) could constitute a third category of mechanisms through which HDAC6 ensures its anti-viral activity.
HDAC6-mediated accumulation of misfolded and ubiquitinated proteins (Boyault et al., 2006) and aggresome formation (Kawaguchi et al., 2003) may also be determinant events in the so-called 'protein conformational diseases'. The pathogenic aggregation of proteins in non-native conformation is generally associated with a whole series of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and prion diseases.
The first evidence for the involvement of HDAC6 in such a disease came from the colocalization of HDAC6 with Lewy bodies of Parkinson's disease. The HDAC6-mediated formation of aggresomes may constitute a protective cell response to cytotoxic effects of misfolded protein accumulation (Kawaguchi et al., 2003) . In addition to promoting aggresome formation, HDAC6 participates in the aggregate degradation by autophagy. This has been shown using a model system expressing aggregation prone huntingtin (htt) involved in the Huntington disease, where these activities of HDAC6 were shown to mediate the autophagic clearance of htt aggregates (Iwata et al., 2005) . HDAC6 therefore appears as a key element in cell protection against the deleterious effects of pathologic protein aggregation in neurodegenerative diseases. The HDAC-dependent functions of HDAC6 on aggresome formation cannot, however, be generalized since, in a model for SOD1 mutant aggresome assembly involved in amyotrophic lateral sclerosis, HDAC inhibitors prevented the accumulation of scattered mSOD1 aggregates in aggresomes, but HDAC6 neutralization by tubacin did not inhibit this process. Moreover, trapoxin, an HDAC inhibitor which does not inhibit HDAC6, showed an efficient inhibition of aggresome formation (Corcoran et al., 2004) . There are, therefore, yet unknown HDAC-dependent mechanisms involved in the control of aggresome formation.
The HDAC6 partner p97/VCP, by modulating HDAC6-ubiquitin interaction, may also play an important role in preventing the pathological accumulation of misfolded proteins. Accordingly, p97/VCP mutations have been identified as causing 'inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia' (Watts et al., 2004) . HDAC6 and p97/VCP, therefore, appear as excellent target molecules in fighting neurodegenerative diseases.
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The cytoskeleton-dependent functions of HDAC6 could also constitute a good target for the treatment of inflammatory disorders depending on interleukin-1b (IL-1b), which is a potent proinflammatory cytokine. Indeed, a treatment with HDAC inhibitors, specifically with an HDAC6 inhibitor, has been shown to significantly reduce the exocytosis of IL-1b-containing secretory lysosomes (Carta et al., 2006) . HDAC6 expression and functions may also be linked to cell transformation. Depending on the type of cancer, the HDAC6 expression level could be considered either as a good prognosis indicator (Zhang et al., 2004) or, in contrast, as a predictor of poor prognosis and tumor aggressiveness (Osada et al., 2004; Hayashi and Yamaguchi, 2006; Sakuma et al., 2006) . Indeed, HDAC6 detection has been reported to correlate with survival in a subset of tamoxifen-treated ER-positive breast cancer patients (Saji et al., 2005) . Another report identified positive HDAC6 staining with decreased survival in ER-positive breast cancer patients, using HDAC6 as a prototypical estrogen-regulated gene (Yoshida et al., 2004) . HDAC6 levels were also found elevated in primary acute myeloid leukemia blasts compared to normal adult cells (Bradbury et al., 2005) .
HDAC6 may also be involved in cell transformation and tumorigenesis through its action on several critical regulatory factors. Accordingly, HDAC6 appears to play a role, directly or indirectly via HSP90, in the control of the stability of HIF-1a, a transcriptional regulator involved in tumor angiogenesis (Qian et al., 2006) , the breast cancer metastasis suppressor 1, BRMS1 (Hurst et al., 2006) , Bcr-Abl, FLT-3, c-Raf and AKT (Bali et al., 2005) .
The specific inhibition of HDAC6 catalytic activity was also shown to synergistically increase the cytotoxicity induced by the proteasome inhibitor bortezomib, therefore potentiating its anti-tumor activity in multiple myeloma (Hideshima et al., 2005) . HDAC6 TDAC activity also contributes to the antiproliferative and anti-mitotic effect of a treatment combining farnesyltransferase inhibitor and taxanes, mainly in taxaneresistant cancer patients (Marcus et al., 2005 (Marcus et al., , 2006 ).
An HDAC6-related deacetylase, HDAC10
HDAC10 was discovered in 2002 (Fischer et al., 2002; Guardiola and Yao, 2002; Kao et al., 2002; Tong et al., 2002) , and the first sequence-based analysis of its structural features revealed similarities with HDAC6. Indeed, among the class II members, the catalytic domain of HDAC10 showed the best homology to that of HDAC6. Moreover, like HDAC6, although partial, there is a duplication of its HDAC homology domain. Finally, HDAC10 presents the same sensitivity regarding HDAC inhibitors as HDAC6; it is resistant to the inhibitory effects of trapoxin B and butyrate, a property that clearly specifies these two members (Guardiola and Yao, 2002; Gurvich et al., 2004) .
Early investigations showed, however, no functional overlap between these two HDACs. For instance, there is no obvious ubiquitin-binding domain in HDAC10 and no TDAC activity could be observed for this enzyme (Guardiola and Yao, 2002; Matsuyama et al., 2002) .
Because of an important lack of knowledge on the cellular functions of HDAC10, it is difficult to conclude on the functional relationship between the two HDACs. However, at least one report shows that both proteins interact with the major cellular phosphatase, PP1, and could therefore be involved in the same regulatory networks (Brush et al., 2004) . A very recent study also led to the identification of two factors involved in the pre-mRNA 3 0 -end processing, the cleavage factor CFIm25 and poly-A polymerase, as in vivo HDAC10 substrates, suggesting a probable function for this protein in the regulation of the 3 0 -end processing machinery (Shimazu et al., 2007) . It would now be interesting to know if these proteins are also HDAC6 substrates. It should, however, be noted that some other HDACs, that is HDAC1, are also capable of deacetylating these substrates (Shimazu et al., 2007) .
Conclusions
HDAC6-dependent modulation of acetylation of its two known substrates, a-tubulin and HSP90, has the potential to initiate a variety of cellular processes with widespread consequences on microtubule-dependent events and HSP90-dependent functions, respectively. Moreover, linked to its ubiquitin-binding activity, these properties of HDAC6 create additional levels of regulation at the crossroads between lysine acetylation and ubiquitination signaling pathways. These properties point to HDAC6 as a particularly well-adapted molecule to coordinate cell responses to stressful stimuli. Its involvement in the management of misfolded protein stress, triggering cellular ubiquitinand microtubule-dependent functions, strongly supports this hypothesis.
It is also very tempting to link these activities of HDAC6 to its HSP90-regulatory capability.
Accordingly, the HDAC6-HSP90 complex could be considered as a sensor of cell response to a variety of stimuli. In fact, dissociation of the complex has been observed in response to different stressful conditions, which lead to HSP90 acetylation (C Boyault and S Khochbin, unpublished results). The released HDAC6 may then trigger all the microtubule-mediated cell responses and, depending on cellular concentrations of p97/VCP, could participate in the management of ubiquitinated proteins, to ensure either their transport to aggresomes, or their delivery to the proteasome and facilitate protein degradation through the autophagy pathway (Figure 2) .
It is therefore expected that future investigations will demonstrate a crucial role for HDAC6 in protective cell responses to many cellular stresses and point to this protein as a valuable therapeutical target for stressrelated pathologies.
